The differentiated thyroid cancer (DTC) is characterized by its clinical and pathological variety. Although relatively rare, is a real public health problem given the high prevalence of nodules in the population. Moreover, although the most CDT has good development, it is essential to identify patients at higher risk. Because of this, many patients receive an overtreatment, and unnecessary, while other patients who would benefit from more aggressive intervention or new molecular therapies slow to be recognized. Thus, the study of markers for diagnosis and prognosis is imperative. For this, there are several proteins that have been shown to differentially expressed in cancer patients. This work aims to study the protein profile of MAGE A3 antigen, p53, MDM2 and KAP1 in patients with differentiated thyroid cancer by checking for possible utility as diagnostic markers and prognosis in order to contribute to the identification of different thyroid cancers, which may lead to new treatment strategies.
News published in Agência FAPESP Newsletter about the scholarship: